Wedbush Maintains Neutral on Sionna Therapeutics, Raises Price Target to $6
Wedbush analyst Laura Chico maintains Sionna Therapeutics (NASDAQ:SION) with a Neutral and raises the price target from $5 to $6.
Stocks · News reference
8-K filing — Sionna Therapeutics, Inc. (SION)
Filed: 2026-09-14 AccNo: 0001193125-26-390577 Size: 200 KB Item 2.05: Cost Associated with Exit or Disposal Activities Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Sionna Therapeutics To Advance SION-451/SION-2222 CF Combo Into Phase 2a; Cuts Workforce By 46% To Extend Cash Runway Into The Second Half Of 2029
Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NBD1 biological activityDual combination Phase 2a trial expected to initiate
SIONNA THERAPEUTICS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Sionna Therapeutics Inc on Behalf of Sionna Therapeutics Stockholders and Encourages Investors to Contact the Firm
Law firm Bragar Eagel & Squire is investigating Sionna Therapeutics after the company announced its SION-719 Phase 2a trial failed to achieve its primary endpoint for sweat chloride reduction. The stock price fell over 91% following the announcement. The firm is encouraging affected shareholders to contact them regarding potential securities law violations.